Key Takeaway
NAC supplementation improved symptoms in schizophrenia patients, supporting its role in psychiatric conditions involving oxidative stress and glutathione deficiency.
Summary
Landmark RCT examining NAC supplementation for schizophrenia, establishing its potential in psychiatric applications.
Methods
- Randomized, double-blind, placebo-controlled
- 140 patients with schizophrenia
- NAC 2g/day for 24 weeks
- Multiple symptom scales
Key Results
- Significant improvement in negative symptoms
- Better global functioning
- Improved quality of life
- Well-tolerated
- Effects mediated by glutathione
Limitations
- Specific psychiatric population
- Adjunctive to antipsychotics
- Long-term effects unknown
- May not generalize